alprazolam and metronidazole

alprazolam has been researched along with metronidazole in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19901 (8.33)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY2
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Blyden, GT; Greenblatt, DJ; Scavone, JM1
Neuhauser, MM; Penzak, SR; Roedler, R1

Reviews

2 review(s) available for alprazolam and metronidazole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?
    The Annals of pharmacotherapy, 2007, Volume: 41, Issue:4

    Topics: Alprazolam; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Metabolic Clearance Rate; Metronidazole; Microsomes, Liver; Substrate Specificity

2007

Trials

1 trial(s) available for alprazolam and metronidazole

ArticleYear
Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam.
    Journal of clinical pharmacology, 1988, Volume: 28, Issue:3

    Topics: Adult; Alprazolam; Drug Interactions; Female; Humans; Lorazepam; Male; Metronidazole; Phenytoin; Random Allocation

1988

Other Studies

9 other study(ies) available for alprazolam and metronidazole

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
    Journal of medicinal chemistry, 2001, Jul-19, Volume: 44, Issue:15

    Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water

2001
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
    Journal of medicinal chemistry, 2002, Jun-20, Volume: 45, Issue:13

    Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding

2002
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010